REFERENCES
- Epenetos AA, Munro Ai, Stewart S, et al. Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabelled monoclonal antibodies. J Clin Oncol 1987; 5: 1890–1899
- Larson SM. Radiolabelled monoclonal anti-tumor antibodies and therapy. J Nucl Med 1985; 26: 538–545
- Buraggi GL, Callegaro L, Mariani G, et al. Imaging with 1311-labeled monoclonal antibodies to a high-molecular-weight mela-noma-associated antigen in patients with melanoma: Efficacy of whole immunoglobulin and its F(ab')2 fragments. Cancer Res 1985; 45: 3378–3387
- Kim JA, Triozzi PL, Martin EW, Jr. Radioimmuoguided surgery for colorectal cancer. Oncology (Williston Park) 1993; 7: 55–60
- Fazio F, Paganelli G. Antibody-guided scintigraphy: Targeting of the “magic bullet”. Eur J Nucl Med 1993; 20: 1138–1140
- Hazra DK, Britton KE, Lahiri VL, et al. Immunotechnological trends in radioimmunotargeting: From ‘magic bullet’ to ‘smart bomb’. Nucl Med Commun 1995; 16: 66–75
- Wessels BW, Rogus RD. Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies. Med Phys 1984; 11: 638–645
- Chinol M, Hnatowich DJ. Generator-produced yttrium-90 for radioimmunotherapy. J Nucl Med 1987; 28: 1465–1470
- Goldenberg DM, Griffiths GL. Radioimmunotherapy of cancer: Arming the missiles. J Nucl Med 1992; 33: 1110–1112
- Chetanneau A, Barbet J, Peltier P, et al. Pretargetted imaging of colorectal cancer recurrences using an 111 In-labelled bivalent hapten and a biospecific antibody conjugate. Nucl Med Commun 1994; 15: 972–980
- Magnani P, Paganelli G, Modorati G, et al. Quantitative comparison of direct antibody labeling and tumor pretargeting in uveal melanoma. J Nucl Med 1996; 37: 967–971
- Wilchek M, Bayer EA. The avidin biotin complex in bioanalytical applications. Anal Biochem 1988; 171: 1–32
- Paganelli G, Magnani P, Zito F, et al. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res 1991; 51: 5960–5966
- Paganelli G, Chinol M, Grana C, et al. Optimization of the three-step pretargeting approach for diagnosis and therapy in cancer patients. J Nucl Med 1995; 36 (Suppl. 5): 225P
- Paganelli G, Grana C, Chinol M, et al. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med 1999; 26: 348–357
- Zagzag D, Friedlander DR, Dosik J, et al. Tenascin-C expression by angiogenic vessels in human astrocytomas and by human brain endothelial cells in vitro. Cancer Res 1996; 56: 182-189
- Grana C, Chinol M, Robertson C, et al. Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: A pilot study. Br] Cancer 2002; 86: 207–212
- Riva P, Franceschi G, Frattarelli M. Loco-regional radioimmu-notherapy of high-grade malignant gliomas using specific mono-clonal antibodies labeled with 90Y: A phase 1 study. Clin Cancer Res 1999; 5 (Suppl. 10): S3275—S3280
- Cokgor I, Akabani G, Kuan CT. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 8106 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol 2000; 18: 3862–3872
- Paganelli G, Belloni C, Magnani P, et al. Two-step tumour targetting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin. Eur J Nucl Med 1992; 19: 322–329
- Paganelli G, Bartolomei M, Ferrari M, et al. Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: Phase 1 study and preliminary therapeutic results. Cancer Biother Radiopharm 2001; 16: 227–235
- Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Eng J Med 2005; 352: 987–996
- Bartolomei M, Mazzetta C, Handkiewicz-Junak D, et al. Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide. Q Nucl Med Mol Imaging 2004; 48: 220–228
- Boiardi A, Bartolomei M, Silvani A, et al. Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma. J Neurooncol 2005; 72: 125–131
- Ferrari M, Cremonesi M, Bartolomei M, et al. Dosimetric model for locoregional treatments of brain tumours with 90Y-conjugates: Clinical application with 90Y-DOTATOC. J Nucl Med 2006; 47: 105–112